logo

Video encyclopedia

BEACOPP

2:20

Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results

1:31

ABVD vs. escBEACOPP in HL: a 10-year study

0:15

Pronounce Medical Words ― BEACOPP Regimen

0:07

Pronounce Medical Words ― BEACOPP

2:31

Hodgkin’s Lymphoma Treatment Adapted after Interim PET-CT

BEACOPP is a chemotherapy regimen for treatment of Hodgkin's lymphoma developed by the German Hodgkin Study Group used for patients in Stages > II or early with unfavorable risk factors. Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. There also exists a more intensive regimen with cycles of 14 days. Usually a course of BEACOPP therapy consists of four, sometimes six to eight cycles, or in combination with ABVD. In some countries BEACOPP still is experimental, in others it is a standard therapy. In the United States, ABVD is generally given instead, because BEACOPP is perceived by practicing oncologists to have the potential to induce more secondary neoplasias. However, the final results from the GHSG HD14 trial indicate that "there were no overall differences in treatment-related mortality or secondary malignancies" of BEACOPP relative to ABVD.
    Explore contextually related video stories in a new eye-catching way. Try Combster now!